SCHEMBL26639998

SCHEMBL26639998

CN1CCc2ncc(Nc3cc4c(cn3)CCN(C(=O)OC(C)(C)C)C4)cc2C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.50
▸ NR1H2 P55055 1/20 0.47
▸ ESR2 Q92731 1/20 0.43
▸ IGF1R P08069 1/20 0.42
▸ MAP3K5 Q99683 3/20 0.41
▸ ROCK2 O75116 1/20 0.40
▸ NAMPT P43490 1/20 0.39
▸ SLC34A1 Q06495 2/20 0.39
▸ PDGFRB P09619 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ RAB9A P51151 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ PTK2 Q05397 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26640594 0.86 ESR2 (0.53) MAPTNR1H2ESR2IGF1RMAP3K5
SCHEMBL26640585 0.84 MAPT (0.61) MAPTNR1H2ESR2IGF1RPDGFRB
SCHEMBL26640168 0.81 MAPT (0.49) MAPTNR1H2ESR2IGF1RMAP3K5
SCHEMBL26640369 0.80 MAPT (0.55) MAPTNR1H2ESR2IGF1RMAP3K5
SCHEMBL31335966 0.80 MAPT (0.53) MAPTNR1H2ESR2IGF1RNAMPT
SCHEMBL31336061 0.79 NR1H2 (0.56) MAPTNR1H2ESR2IGF1RMAP3K5
SCHEMBL25156583 0.77 MAPT (0.49) MAPTNR1H2ESR2IGF1RROCK2
SCHEMBL30407628 0.77 MAPT (0.49) MAPTNR1H2ESR2IGF1RROCK2
SCHEMBL26640521 0.77 MAPT (0.49) MAPTNR1H2ESR2IGF1RMAP3K5
SCHEMBL25428060 0.77 NR1H2 (0.54) MAPTNR1H2ESR2IGF1RMAP3K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 — — EP disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 — — WO disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 MAPT 3283/4885NR1H2 2066/4885ESR2 3671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback